Skip to main content

03.05.2024 | Original Article

Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH

verfasst von: Dan Tomomasa, Kay Tanita, Yuriko Hiruma, Akihiro Hoshino, Ko Kudo, Shohei Azumi, Mitsutaka Shiota, Masayoshi Yamaoka, Katsuhide Eguchi, Masataka Ishimura, Yuka Tanaka, Keiji Iwatsuki, Keisuke Okuno, Asahito Hama, Ken-Ichi Sakamoto, Takashi Taga, Kimitoshi Goto, Haruka Ota, Akihiro Ichiki, Kaori Kanda, Takako Miyamura, Saori Endo, Hidenori Ohnishi, Yoji Sasahara, Ayako Arai, Benjamin Fornier, Ken-Ichi Imadome, Tomohiro Morio, Sylvain Latour, Hirokazu Kanegane

Erschienen in: International Journal of Hematology

Einloggen, um Zugang zu erhalten

Abstract

When Epstein-Barr virus (EBV) infection is suspected, identification of infected cells is important to understand the pathogenesis, determinine the treatment strategy, and predict the prognosis. We used the PrimeFlow™ RNA Assay Kit with a probe to detect EBV-encoded small RNAs (EBERs) and multiple surface markers, to identify EBV-infected cells by flow cytometry. We analyzed a total of 24 patients [11 with chronic active EBV disease (CAEBV), 3 with hydroa vacciniforme lymphoproliferative disorder, 2 with X-linked lymphoproliferative disease type 1 (XLP1), 2 with EBV-associated hemophagocytic lymphohistiocytosis, and 6 with posttransplant lymphoproliferative disorder (PTLD)]. We compared infected cells using conventional quantitative PCR methods and confirmed that infected cell types were identical in most patients. Patients with CAEBV had widespread infection in T and NK cells, but a small amount of B cells were also infected, and infection in patients with XLP1 and PTLD was not limited to B cells. EBV-associated diseases are believed to be complex pathologies caused by EBV infecting a variety of cells other than B cells. We also demonstrated that infected cells were positive for HLA-DR in patients with CAEBV. EBER flow FISH can identify EBV-infected cells with high sensitivity and is useful for elucidating the pathogenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Fournier B, Latour S. Immunity to EBV as revealed by immunedeficiencies. Curr Opin Immunol. 2021;72:107–15.CrossRefPubMed Fournier B, Latour S. Immunity to EBV as revealed by immunedeficiencies. Curr Opin Immunol. 2021;72:107–15.CrossRefPubMed
3.
Zurück zum Zitat Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods. 1998;73:163–74.CrossRefPubMed Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods. 1998;73:163–74.CrossRefPubMed
4.
Zurück zum Zitat Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis. 2009;200:1078–87.CrossRefPubMed Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis. 2009;200:1078–87.CrossRefPubMed
5.
Zurück zum Zitat Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Cancer Sci. 2012;103:1481–1448.CrossRefPubMedPubMedCentral Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Cancer Sci. 2012;103:1481–1448.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Fournier B, Boutboul D, Bruneau J, Miot C, Boulanger C, Malphettes M, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217: e20192262.CrossRefPubMedPubMedCentral Fournier B, Boutboul D, Bruneau J, Miot C, Boulanger C, Malphettes M, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217: e20192262.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Ohga S, Ishimura M, Yoshimoto G, Miyamoto T, Takada H, Tanaka T, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood. J Clin Virol. 2011;51:31–7.CrossRefPubMed Ohga S, Ishimura M, Yoshimoto G, Miyamoto T, Takada H, Tanaka T, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood. J Clin Virol. 2011;51:31–7.CrossRefPubMed
8.
Zurück zum Zitat Kanegane H, Wado T, Nunogami K, Seki H, Taniguchi N, Tosato G. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol. 1996;95:116–22.CrossRefPubMed Kanegane H, Wado T, Nunogami K, Seki H, Taniguchi N, Tosato G. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol. 1996;95:116–22.CrossRefPubMed
9.
Zurück zum Zitat Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.CrossRefPubMedPubMedCentral Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227–44.CrossRefPubMed Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227–44.CrossRefPubMed
11.
Zurück zum Zitat Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, et al. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2014;134:1381–7.CrossRefPubMedPubMedCentral Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, et al. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2014;134:1381–7.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed
13.
Zurück zum Zitat Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–55.CrossRefPubMed Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–55.CrossRefPubMed
14.
Zurück zum Zitat Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.CrossRefPubMedPubMedCentral Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Watanabe Y, Sasahara Y, Satoh M, Looi CY, Katayama S, Suzuki T, et al. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study. Eur J Haematol. 2013;91:242–8.CrossRefPubMed Watanabe Y, Sasahara Y, Satoh M, Looi CY, Katayama S, Suzuki T, et al. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study. Eur J Haematol. 2013;91:242–8.CrossRefPubMed
16.
Zurück zum Zitat Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.CrossRefPubMed Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.CrossRefPubMed
17.
Zurück zum Zitat Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673–86.CrossRefPubMed Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673–86.CrossRefPubMed
18.
Zurück zum Zitat Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13.CrossRefPubMed Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13.CrossRefPubMed
19.
Zurück zum Zitat J Wang M Su N Wei H Yan J Zhang Y Gong et al 2023 Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells [published online ahead of print, 2023 Oct 12]. Blood blood.2023021074. J Wang M Su N Wei H Yan J Zhang Y Gong et al 2023 Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells [published online ahead of print, 2023 Oct 12]. Blood blood.2023021074.
20.
Zurück zum Zitat Iwatsuki K, Miyake T, Hirai Y, Yamamoto T. Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Eur J Dermatol. 2019;29:21–8.CrossRefPubMed Iwatsuki K, Miyake T, Hirai Y, Yamamoto T. Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Eur J Dermatol. 2019;29:21–8.CrossRefPubMed
21.
Zurück zum Zitat Toga A, Wada T, Sakakibara Y, Mase S, Araki R, Tone Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis. 2010;201:1923–32.CrossRefPubMed Toga A, Wada T, Sakakibara Y, Mase S, Araki R, Tone Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis. 2010;201:1923–32.CrossRefPubMed
22.
Zurück zum Zitat Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M, et al. Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae. 2012;3:1.CrossRefPubMedPubMedCentral Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M, et al. Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae. 2012;3:1.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMedPubMedCentral Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71(6):4657–62.CrossRefPubMedPubMedCentral Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71(6):4657–62.CrossRefPubMedPubMedCentral
Metadaten
Titel
Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH
verfasst von
Dan Tomomasa
Kay Tanita
Yuriko Hiruma
Akihiro Hoshino
Ko Kudo
Shohei Azumi
Mitsutaka Shiota
Masayoshi Yamaoka
Katsuhide Eguchi
Masataka Ishimura
Yuka Tanaka
Keiji Iwatsuki
Keisuke Okuno
Asahito Hama
Ken-Ichi Sakamoto
Takashi Taga
Kimitoshi Goto
Haruka Ota
Akihiro Ichiki
Kaori Kanda
Takako Miyamura
Saori Endo
Hidenori Ohnishi
Yoji Sasahara
Ayako Arai
Benjamin Fornier
Ken-Ichi Imadome
Tomohiro Morio
Sylvain Latour
Hirokazu Kanegane
Publikationsdatum
03.05.2024
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03786-0

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.